Scientific deep-dive

Retatrutide vs Ozempic: T2D Phase 2 Cross-Trial Evidence (vs SUSTAIN-7)

Indirect T2D comparison: retatrutide 12 mg -2.02% HbA1c (phase 2) and -18.8% body weight at 80 wk (TRIUMPH-2, placebo-controlled) vs Ozempic 1.0 mg -1.8% HbA1c / -6.5 kg (SUSTAIN-7). Ozempic FDA-approved 2017; retatrutide investigational.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
12 min read·15 citations

This cross-trial comparison sits in Weight Loss Rankings' living editorial database — 1,180+ research articles and 640+ clinically-verified GLP-1 telehealth providers, sourced only from primary FDA labels, ClinicalTrials.gov registrations, and peer-reviewed PubMed literature.

Ozempic (semaglutide) is FDA-approved for type 2 diabetes since December 2017 and is widely available today. Retatrutide is investigational and not FDA-approved. The first randomized head-to-head trial, TRANSCEND-T2D-2, now has topline results: on October 28, 2026, Lilly reported that in 1,298 adults with type 2 diabetes, A1C fell 2.2% on retatrutide 9 mg and 12 mg versus 1.8% on Ozempic 2 mg at 80 weeks, and body weight fell 19.5% and 20.9% versus 9.4%[15]. Those are company figures from a press release and have not yet been peer-reviewed; our news report on the TRANSCEND-T2D-2 results covers the design and caveats. Retatrutide's other phase 3 trial in adults with obesity and type 2 diabetes, TRIUMPH-2 (Lancet 2026), was placebo-controlled and reported 18.8% weight loss on 12 mg versus 5.1% on placebo at 80 weeks[11]. Until the head-to-head data are published, most of the HbA1c numbers below remain an indirect cross-trial comparison between the Rosenstock 2023 phase 2 retatrutide T2D trial and the SUSTAIN semaglutide phase 3 program.

At a glance

  • Retatrutide HbA1c at 24 wk (phase 2 T2D): −2.02% at 12 mg dose vs −1.41% on dulaglutide 1.5 mg and −0.01% on placebo (Rosenstock 2023, n=281).[1]
  • Ozempic HbA1c at 40 wk (SUSTAIN-7): −1.5% at 0.5 mg and −1.8% at 1.0 mg vs dulaglutide −1.1% / −1.4% (Pratley 2018, n=1,201).[5]
  • Weight change at 36 wk (retatrutide phase 2): −16.94% body weight at 12 mg vs −3.00% placebo and −2.02% dulaglutide.[1]
  • Weight change at 40 wk (Ozempic SUSTAIN-7): −4.6 kg at 0.5 mg and −6.5 kg at 1.0 mg vs dulaglutide −2.3 kg / −3.0 kg.[5]
  • Retatrutide phase 3 in T2D (TRIUMPH-2, 80 wk): −11.9% / −16.8% / −18.8% body weight at 4 / 9 / 12 mg vs −5.1% on placebo (Bellido 2026, n=1,152, placebo-controlled).[11]
  • Retatrutide phase 3 HbA1c (TRANSCEND-T2D-1, 40 wk): −1.94% at 12 mg vs −0.81% on placebo as monotherapy (Bajaj 2026, n=537, placebo-controlled) — the same 40-week duration as SUSTAIN-7, though a different population and no active comparator.[14]
  • Head-to-head topline (TRANSCEND-T2D-2, 80 wk): A1C −2.2% on retatrutide 9 mg and 12 mg vs −1.8% on Ozempic 2 mg; body weight −19.5% / −20.9% vs −9.4%; stopped for adverse events 4.8% / 7.9% vs 2.7% (Lilly press release, Oct 28 2026, not yet peer-reviewed).[15]
  • Mechanism: retatrutide is a triple GIP + GLP-1 + glucagon receptor agonist; Ozempic is a GLP-1 receptor agonist only.
  • Approval: Ozempic FDA-approved Dec 5 2017 (ApplNo 209637); retatrutide not approved anywhere as of October 2026; Lilly plans to submit a Biologics License Application in Q1 2027.[8][12]
  • Cardiovascular evidence: Ozempic has SUSTAIN-6 (3,297 T2D, NEJM 2016) confirming non-inferiority + reduced MACE; retatrutide's cardiovascular and kidney outcomes trial (TRIUMPH-Outcomes) is still ongoing.[7][13]

Approval status — Ozempic FDA-approved 2017 for T2D, retatrutide investigational

Ozempic (semaglutide subcutaneous, Novo Nordisk) is FDA- approved for adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control, and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease. The original FDA approval date is December 5, 2017 (Application Number 209637); the current prescribing information lives on the DailyMed Ozempic SetID and reflects all post-approval label expansions.[8][9]

Ozempic and Wegovy are the same molecule (semaglutide) at different doses with different indications: Ozempic is approved for T2D at weekly doses of 0.25 / 0.5 / 1.0 / 2.0 mg, while Wegovy is approved for chronic weight management at weekly doses up to 7.2 mg. For a patient with type 2 diabetes seeking an FDA-approved GLP-1 receptor agonist, Ozempic is the labeled product; Wegovy is the labeled product when the goal is weight loss in adults with obesity, or overweight with at least one weight-related comorbidity (in practice BMI ≥ 30, or ≥ 27 with a comorbidity, the STEP 1 trial cutoffs; the label gives no BMI numbers). This article focuses on the T2D comparison.

Retatrutide (Eli Lilly, code LY3437943) is investigational. It has no FDA approval, no European Medicines Agency approval, and no approval in any jurisdiction worldwide as of October 2026. The TRIUMPH-2 phase 3 T2D pivotal trial (NCT05929079) completed in June 2026 and was published in The Lancet (Bellido 2026, PMID 42810372): 1,152 adults with obesity or overweight and type 2 diabetes lost 11.9%, 16.8%, and 18.8% of body weight on 4, 9, and 12 mg versus 5.1% on placebo at 80 weeks.[10][11] TRIUMPH-2 was placebo-controlled. Two retatrutide T2D trials have an active comparator: the Rosenstock 2023 phase 2 trial described below, which used dulaglutide, and TRANSCEND-T2D-2, which compared retatrutide directly with Ozempic 2 mg and so far has only topline results (next section). Lilly plans to submit a Biologics License Application to the FDA in Q1 2027.[12] Retatrutide is not eligible for legal 503A pharmacy compounding (not on the FDA bulk-substance list, not a discontinued FDA-approved drug); see our retatrutide sourcing / regulatory analysis for the legal detail.

The head-to-head trial: TRANSCEND-T2D-2 topline results

TRANSCEND-T2D-2 (NCT06260722) is a randomized, open-label phase 3 trial in 1,298 adults with type 2 diabetes inadequately controlled with metformin, with or without an SGLT2 inhibitor, and a baseline A1C of 7.0% to 10.5%. Participants were randomized 2:2:1 to weekly retatrutide 9 mg, retatrutide 12 mg or Ozempic 2 mg, the highest approved Ozempic dose. Lilly announced topline results on October 28, 2026.[15]

  • A1C at 80 wk (primary endpoint): −2.2% on both retatrutide doses vs −1.8% on Ozempic, from an average baseline of 8.3%.[15]
  • Body weight at 80 wk: −19.5% (9 mg) and −20.9% (12 mg) vs −9.4% on Ozempic, from an average baseline of 102.4 kg.[15]
  • Stopped because of adverse events: 4.8% (9 mg) and 7.9% (12 mg) vs 2.7% on Ozempic.[15]
  • Common adverse events: diarrhea 28.3% and 32.7% vs 26.4%; nausea 21.2% and 23.8% vs 21.3%; dysesthesia 4.8% and 6.5% vs 2.7%.[15]

These figures come from Lilly's press release, not a journal article. They use the efficacy estimand, which estimates the effect had every participant stayed on treatment, and the trial was open-label. Lilly says detailed results will be presented at a future medical meeting and published in a peer-reviewed journal, so treat the numbers as provisional until then.[15]

HbA1c reduction — cross-trial comparison

Until TRANSCEND-T2D-2 is published, the cleanest peer-reviewed comparison is the Rosenstock 2023 phase 2 retatrutide T2D trial (PMID 37385280) read against the SUSTAIN semaglutide phase 3 program. The retatrutide trial used dulaglutide 1.5 mg as the active comparator (not semaglutide), so the cross-trial bridge to Ozempic runs through SUSTAIN-7 (semaglutide vs dulaglutide; Pratley 2018, PMID 29397376).

  • Retatrutide 12 mg — 24-wk HbA1c: −2.02% (least-squares mean change from baseline) vs −1.41% on dulaglutide 1.5 mg and −0.01% on placebo. Retatrutide 8 mg slow-escalation was −1.99%; 8 mg fast-escalation was −1.88%. Significantly greater than dulaglutide at the 8 mg slow (P=0.0019) and 12 mg (P=0.0002) doses.[1]
  • Ozempic 1.0 mg — 40-wk HbA1c (SUSTAIN-7): −1.8% vs dulaglutide 1.5 mg −1.4% (estimated treatment difference −0.41 pp; P<0.0001).[5]
  • Ozempic 0.5 mg — 40-wk HbA1c (SUSTAIN-7): −1.5% vs dulaglutide 0.75 mg −1.1% (ETD −0.40 pp; P<0.0001).[5]

The headline difference, taken at face value: retatrutide 12 mg produced about 0.2 percentage points more HbA1c reduction than Ozempic 1.0 mg at the highest tested dose (−2.02% vs −1.8%). The differential is small but consistent in direction with what would be expected from a triple-agonist mechanism layering glucagon-receptor signaling on the GLP-1 backbone.

Both molecules also produced meaningful HbA1c reductions against placebo in monotherapy: Ozempic in SUSTAIN-1 (Sorli 2017, PMID 28110911) and in SUSTAIN-2 vs sitagliptin (Ahrén 2017, PMID 28385659), and in SUSTAIN-8 vs canagliflozin (Lingvay 2019, PMID 31540867). Retatrutide's T2D evidence now spans the Rosenstock 2023 phase 2, the placebo-controlled phase 3 TRIUMPH-2 and TRANSCEND-T2D-1 trials, and the TRANSCEND-T2D-2 head-to-head topline.[3][4][6][11][14][15]

Weight loss — cross-trial comparison

Weight loss is where the magnitude gap widens. Both trials are in patients with type 2 diabetes (not obesity), but the designs and time points are different.

  • Retatrutide 12 mg — 36-wk body weight: −16.94% mean change from baseline vs −3.00% placebo and −2.02% dulaglutide 1.5 mg. All retatrutide doses ≥4 mg significantly greater than dulaglutide (P<0.0001).[1]
  • Retatrutide 8 mg — 36-wk body weight: −16.81% (slow escalation) / −16.34% (fast escalation).[1]
  • Ozempic 1.0 mg — 40-wk weight (SUSTAIN-7): −6.5 kg vs dulaglutide 1.5 mg −3.0 kg (P<0.0001). At baseline body weight ~95 kg this is roughly −6.8% mean change.[5]
  • Ozempic 0.5 mg — 40-wk weight (SUSTAIN-7): −4.6 kg vs dulaglutide 0.75 mg −2.3 kg (P<0.0001), roughly −4.8% mean change.[5]

On the closest available cross-trial comparison, retatrutide 12 mg at 36 weeks produced roughly −17% mean body weight change in T2D, while Ozempic 1.0 mg at 40 weeks in T2D produced roughly −7%. That is a ~10 percentage-point absolute weight-loss advantage for retatrutide on indirect comparison — but the comparison should be read with all the cross-trial caveats below.

The Coskun 2025 body-composition substudy of the Rosenstock phase 2 trial (PMID 40609566) also reported DXA-measured fat mass changes: 23.2% fat-mass reduction at retatrutide 12 mg and 26.1% at 8 mg pooled vs 4.5% placebo, with the lean-mass-to-weight-loss ratio similar to other obesity therapies — reassuring against the hypothesis that the magnitude of weight loss reflects disproportionate lean-mass loss.[2]

Mechanism — triple-class (GIP + GLP-1 + glucagon) vs GLP-1-only

Ozempic (semaglutide) is a single-receptor agonist at the GLP-1 receptor. GLP-1 receptor activation slows gastric emptying, increases glucose-dependent insulin secretion, suppresses glucagon at hyperglycemia, and reduces appetite through hypothalamic and brainstem signaling. Semaglutide is the most-studied GLP-1 receptor agonist in the modern era, with a phase 3 program (SUSTAIN 1–10) covering monotherapy, dual oral comparators, dual injectable comparators, insulin add-on, renal-impairment populations, and a cardiovascular outcomes trial.

Retatrutide adds two more receptor targets. It is a triple agonist at GIP, GLP-1, and glucagon receptors. The GIP component layers on additional weight-loss and glucose-dependent insulin effects similar to tirzepatide. The glucagon-receptor component is what differentiates retatrutide from anything currently FDA-approved: glucagon-receptor activation increases hepatic energy expenditure, promotes lipolysis, and accelerates hepatic fatty-acid oxidation. The net pharmacologic profile is greater weight loss and likely greater hepatic-fat reduction at the cost of a steeper tolerability curve and more prominent non-GI signals (the dysesthesia/paresthesia finding in the retatrutide obesity program; mild ALT elevations).

See our deep-dive on the retatrutide triple-agonist mechanism evidence for the receptor pharmacology and the structural-biology substrate.

Trial duration and populations differ — caveats

The cross-trial comparison sits on several caveats every reader should know before they treat the numbers as a clean head-to-head.

  • Phase 2 vs phase 3. The retatrutide T2D number is a phase 2 trial (n=281) — exploratory by design. The Ozempic comparison number is from a phase 3 confirmatory trial (n=1,201). Phase 2 effect sizes often shrink in phase 3. TRIUMPH-2 has now confirmed substantial phase 3 weight loss in T2D versus placebo, but it had no semaglutide arm. The 40-week phase 3 TRANSCEND-T2D-1 monotherapy trial (HbA1c −1.94% at 12 mg vs −0.81% placebo) is closer in duration to SUSTAIN-7, but its population (diet-and-exercise only, mean diabetes duration 2.5 years) differs, so neither settles the HbA1c comparison with Ozempic.[1][11][14]
  • Different active comparators. Rosenstock 2023 used dulaglutide 1.5 mg as the active arm; SUSTAIN-7 also used dulaglutide. The cross-trial bridge therefore reads "retatrutide vs dulaglutide vs semaglutide," adding an extra inferential step.
  • Different durations. Retatrutide primary endpoint at 24 wk + body-weight endpoint at 36 wk; SUSTAIN-7 primary endpoint at 40 wk. GLP-1 weight-loss curves typically continue downward past 40 wk, so the retatrutide-vs-Ozempic weight-loss gap may narrow or widen at later time points.
  • Different baseline populations. Rosenstock 2023 mean baseline HbA1c ~8.3% / mean BMI ~35; SUSTAIN-7 mean baseline HbA1c ~8.2% / mean BMI ~33. These are comparable but not identical.
  • One head-to-head, not yet peer-reviewed. TRANSCEND-T2D-2 compared retatrutide directly with Ozempic 2 mg and reported topline results on October 28, 2026. Those are company data that have not been peer-reviewed; every other comparison on this page is indirect.[15]

Side-effect profile — cross-trial comparison

Both molecules show the GLP-1-class GI signal: nausea, vomiting, diarrhea, constipation. The magnitudes differ.

  • Retatrutide phase 2 (pooled all doses): any GI adverse event in ~35% of retatrutide participants vs 13% placebo and 35% dulaglutide. Range across doses: 13% (at 0.5 mg) to 50% (at 8 mg fast-escalation).[1]
  • Ozempic SUSTAIN-7 (1.0 mg): nausea ~21%, diarrhea ~14%, vomiting ~10%, with overall GI-AE rate broadly comparable to dulaglutide.[5]
  • No severe hypoglycemia was reported in the retatrutide phase 2; the same finding is consistent across the SUSTAIN program with semaglutide monotherapy or background metformin — the hypoglycemia signal in either GLP-1 class is largely driven by concurrent insulin or sulfonylurea exposure.[1][5]
  • Dysesthesia / paresthesia. Dysesthesia (abnormal skin sensation) is a retatrutide signal that was not a prominent finding in the SUSTAIN semaglutide program: in the T2D phase 3 TRIUMPH-2, it occurred in 4%, 6%, and 7% at 4, 9, and 12 mg vs 1% on placebo.[11] The Rosenstock 2023 phase 2 T2D trial did not report this signal at comparable rates, but the trial was smaller and shorter than TRIUMPH-2.

Both molecules carry the standard GLP-1 class label warnings in the United States — pancreatitis (post-marketing, unconfirmed causal), gallbladder disease, acute kidney injury in the setting of severe GI volume loss, hypoglycemia when combined with insulin or sulfonylurea, retinopathy worsening in the SUSTAIN-6 dataset. See the GLP-1 side-effects Q&A hub and our GLP-1 side-effect timeline tool for the per-week onset pattern.

Cardiovascular outcomes — Ozempic has SUSTAIN-6, retatrutide CVOT pending

Ozempic has a completed cardiovascular outcomes trial: SUSTAIN-6 (Marso 2016, NEJM, PMID 27633186) randomized 3,297 adults with type 2 diabetes at high cardiovascular risk to semaglutide 0.5 mg or 1.0 mg vs placebo over 104 weeks. Primary outcome (composite of CV death, non-fatal MI, non-fatal stroke) occurred in 6.6% of semaglutide patients vs 8.9% on placebo (hazard ratio 0.74, 95% CI 0.58–0.95, P<0.001 for non-inferiority). The FDA label was subsequently updated to add the cardiovascular MACE-reduction indication for adults with T2D and established CV disease.[7][9]

Retatrutide has no completed cardiovascular outcomes trial. TRIUMPH-3 (NCT05882045) enrolled people with severe obesity and established CV disease, but its primary endpoint was body-weight change, not cardiovascular events. The event-driven outcomes trial, TRIUMPH-Outcomes (NCT06383390), is still ongoing in adults with BMI ≥ 27 and atherosclerotic cardiovascular disease and/or chronic kidney disease.[13] Until it reads out, retatrutide cannot claim a MACE-reduction benefit in T2D. This is a meaningful practical distinction: for a T2D patient with established atherosclerotic cardiovascular disease, Ozempic is the only molecule of the two with formal cardiovascular evidence.

Cost and availability today

Ozempic is commercially available across U.S. retail and specialty pharmacies. The Novo Nordisk list price for a monthly Ozempic pen is approximately $1,028/month before rebates or insurance (NovoCare self-pay is $199 for the first two months, then $349–$499), though most commercial-insurance patients pay $25–$200/month after manufacturer savings cards and prior-authorization approval. NovoCare and most major payers cover Ozempic for FDA-on-label T2D use; coverage for off-label weight loss is generally denied. Compounded semaglutide pricing in 2026 has narrowed substantially after FDA removed semaglutide from the drug shortages list in early 2025 — the compounded market is shrinking under enforcement pressure.

Retatrutide is not commercially available anywhere. There is no FDA-approved brand product, no list price, no pharmacy stocking it, and no legal 503A compounding pathway. The only legal access to retatrutide today is enrollment in an active clinical trial. Lilly plans to submit a Biologics License Application in Q1 2027[12], so commercial availability depends on the FDA review that follows. See our retatrutide approval and access timeline for the current filing status.

Magnitude comparison

Retatrutide phase 2 T2D (Rosenstock 2023) vs Ozempic phase 3 T2D (SUSTAIN-7, Pratley 2018) — HbA1c and weight at end of trial. Phase 2 vs phase 3, 36 vs 40 weeks, indirect comparison.[1][5]

  • Retatrutide 12 mg — HbA1c reduction (24 wk)2.02 % absolute
    Phase 2 T2D (Rosenstock 2023)
  • Ozempic 1.0 mg — HbA1c reduction (40 wk, SUSTAIN-7)1.80 % absolute
  • Retatrutide 12 mg — body weight change (36 wk)16.94 % TBWL
  • Ozempic 1.0 mg — body weight change (40 wk, SUSTAIN-7)6.80 % TBWL (est)
    ~6.5 kg at baseline ~95 kg
Retatrutide phase 2 T2D (Rosenstock 2023) vs Ozempic phase 3 T2D (SUSTAIN-7, Pratley 2018) — HbA1c and weight at end of trial. Phase 2 vs phase 3, 36 vs 40 weeks, indirect comparison.

When Ozempic makes more sense (FDA-approved, accessible, T2D-specific)

For most patients with type 2 diabetes today, Ozempic is the practical answer — not because the comparative pharmacology favors it, but because it is the molecule a prescriber can actually write today.

  • You have T2D and need an FDA-approved option now. Ozempic is on-label, available at any U.S. retail pharmacy, has commercial-insurance coverage pathways, and is the standard of care for incretin-naive T2D patients who have not reached HbA1c target on metformin.
  • You have established cardiovascular disease. SUSTAIN-6 supports an FDA-labeled MACE-reduction indication for Ozempic in adults with T2D and established CV disease. Retatrutide has no analogous T2D-population CVOT yet.[7]
  • You want predictable monthly costs. Even before insurance, Ozempic has a published list price and manufacturer savings programs. Retatrutide has neither.
  • You want the longest post-marketing safety record. Semaglutide has been FDA-approved since 2017, with millions of patient-years of post-marketing exposure across Ozempic, Wegovy, and Rybelsus. Retatrutide's total clinical exposure is a few thousand trial patients over ~5 years.
  • You have a prior intolerance to glucagon-receptor adjacent signals. The retatrutide phase 2 trial did not report comparable rates, but TRIUMPH-2 found dysesthesia in 7% on 12 mg vs 1% on placebo, a signal to watch.

The honest reverse case: if you have T2D plus class III obesity (BMI ≥ 40) and your treatment goal is the largest possible weight loss combined with HbA1c reduction, and you can wait for FDA review of Lilly's planned 2027 filing, retatrutide may become a preferred option if it is approved; TRIUMPH-2 showed 18.8% average weight loss on 12 mg in adults with T2D. Until then, Wegovy or Zepbound already offer ~15–21% TBWL with FDA approval today.

Practical takeaway

For type 2 diabetes in October 2026: Ozempic is FDA-approved, commercially available, supported by the SUSTAIN phase 3 program and a positive cardiovascular outcomes trial, and backed by ~9 years of post-marketing experience. Retatrutide's T2D data are promising — −2.02% HbA1c at 12 mg in a 281-patient phase 2 trial and −18.8% body weight at 12 mg over 80 weeks in the placebo-controlled phase 3 TRIUMPH-2 — but no regulatory approval exists anywhere, and there is no legal access pathway outside of an active trial. A patient should not delay treatment in expectation of retatrutide; the GLP-1 / dual / triple class has FDA-approved options available today that produce clinically meaningful HbA1c and weight outcomes. For weight management without diabetes, the parallel question is covered in retatrutide vs Wegovy.

Drug selection for type 2 diabetes is highly individualized — comorbidity profile (cardiovascular disease, chronic kidney disease, heart failure), baseline HbA1c, insulin therapy, and insurance coverage all matter. Discuss any treatment change with your prescribing clinician.

Further reading

Our reviews

Providers that offer semaglutide

Telehealth providers we’ve reviewed. Each opens our full, independent review.

We may earn a commission from featured partners. Learn more

See the full ranking →

Frequently Asked Questions

Indirect cross-trial comparison favors retatrutide at the highest tested doses: -2.02% HbA1c at 24 wk on retatrutide 12 mg (Rosenstock 2023 phase 2, n=281) vs -1.8% HbA1c at 40 wk on Ozempic 1.0 mg (SUSTAIN-7 phase 3, n=1,201). But this is phase 2 vs phase 3, different trials, different durations, different active comparators. The phase 3 TRIUMPH-2 trial (Lancet 2026) compared retatrutide with placebo, not Ozempic. The first head-to-head trial, TRANSCEND-T2D-2, reported topline results on October 28, 2026: at 80 weeks A1C fell 2.2% on retatrutide 9 mg and 12 mg versus 1.8% on Ozempic 2 mg, and weight fell 19.5% and 20.9% versus 9.4%. Those are Lilly's press-release figures and have not yet been peer-reviewed. Retatrutide is also not FDA-approved and is not legally available outside an active clinical trial; Ozempic has been FDA-approved for T2D since December 2017.
Yes. Ozempic (semaglutide subcutaneous, Novo Nordisk) was FDA-approved on December 5, 2017 (Application Number 209637) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The label was later expanded to include reduction in major adverse cardiovascular events in adults with T2D and established cardiovascular disease, based on the SUSTAIN-6 trial. Current dosing is 0.25 / 0.5 / 1.0 / 2.0 mg once weekly subcutaneously.
No. Retatrutide (Eli Lilly, code LY3437943) is investigational and has not been approved by FDA, EMA, or any regulatory authority worldwide as of October 2026. The TRIUMPH-2 phase 3 T2D trial (NCT05929079) was published in The Lancet in 2026, and Lilly plans to submit a Biologics License Application to the FDA in Q1 2027. There is no legal 503A pharmacy compounding pathway for retatrutide.
On indirect cross-trial comparison: retatrutide 12 mg produced -16.94% body weight at 36 weeks in the Rosenstock 2023 phase 2 T2D trial. Ozempic 1.0 mg produced about -6.5 kg (roughly -6.8% from baseline weight ~95 kg) at 40 weeks in SUSTAIN-7. That's a ~10 percentage-point absolute advantage for retatrutide on indirect comparison. In the longer, placebo-controlled phase 3 TRIUMPH-2 trial, retatrutide 12 mg produced -18.8% body weight at 80 weeks versus -5.1% on placebo. In the head-to-head TRANSCEND-T2D-2 trial, Lilly's topline results (not yet peer-reviewed) showed 19.5% weight loss on 9 mg and 20.9% on 12 mg versus 9.4% on Ozempic 2 mg at 80 weeks.
Both are weekly subcutaneous injectable peptides used for type 2 diabetes (Ozempic on label; retatrutide investigational), but they have different mechanisms. Ozempic is a single GLP-1 receptor agonist. Retatrutide is a triple GIP + GLP-1 + glucagon receptor agonist — it activates two additional receptors, including glucagon, which contributes to greater weight loss and hepatic-fat reduction at the cost of more pronounced side effects in the obesity program.
Yes. SUSTAIN-6 (Marso 2016, NEJM, PMID 27633186) randomized 3,297 adults with type 2 diabetes at high cardiovascular risk to semaglutide 0.5/1.0 mg or placebo over 104 weeks. Major adverse cardiovascular events occurred in 6.6% on semaglutide vs 8.9% on placebo (hazard ratio 0.74, 95% CI 0.58-0.95). The FDA label was updated to include MACE reduction in adults with T2D and established CV disease. Retatrutide has no analogous T2D-population CVOT yet.
Same molecule (semaglutide) but different doses and different FDA-approved indications. Ozempic is approved for type 2 diabetes at 0.25 / 0.5 / 1.0 / 2.0 mg weekly. Wegovy is approved for chronic weight management in adults with obesity or overweight with comorbidity at doses up to 7.2 mg weekly. Insurance coverage differs accordingly: Ozempic is reimbursed when the indication is T2D; Wegovy is reimbursed when the indication is weight loss.
Not legally. Retatrutide is not on the FDA 503A bulk drug substances list, is not a component of any FDA-approved drug, and is not a discontinued FDA-approved drug, so it does not satisfy the 503A pharmacy compounding criteria. Any product marketed as 'compounded retatrutide' in 2026 lacks an FDCA legal basis and carries unverified identity, potency, and sterility risk. The only legal access pathway today is enrollment in an active clinical trial.
This is a question for your prescribing clinician. On indirect comparison, retatrutide may offer greater weight reduction than Ozempic at maximum tested dose, but it will likely also carry a steeper tolerability profile (dysesthesia occurred in 7% on 12 mg vs 1% on placebo in the T2D trial TRIUMPH-2, and 6.5% vs 2.7% on Ozempic 2 mg in the TRANSCEND-T2D-2 topline). For T2D patients with established cardiovascular disease, Ozempic's SUSTAIN-6 evidence is currently unmatched. The decision will hinge on individual treatment goals, comorbidities, and coverage.
Retatrutide's triple mechanism adds glucagon-receptor activation, which is thought to increase energy expenditure and hepatic fat oxidation on top of the appetite suppression it shares with GLP-1 drugs — so mechanistically it may drive fat loss beyond a GLP-1-only drug like Ozempic. A DXA body-composition substudy of the Rosenstock 2023 phase 2 trial (Coskun 2025, PMID 40609566) reported large fat-mass reductions — about 23% at 12 mg — with a lean-to-total loss ratio similar to other obesity therapies. Important caveat: retatrutide is investigational, not FDA-approved, and these body-composition figures come from a phase 2 substudy.
Because retatrutide is investigational and not FDA-approved, no one can legally take it outside an active clinical trial, and trials apply their own eligibility screening. Based on its GLP-1-class mechanism, the expected contraindications mirror the class: a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), and caution with a history of pancreatitis or serious gastrointestinal disease. The definitive contraindications will be set by the FDA-approved label if and when retatrutide is approved; any decision belongs to a prescribing clinician.
Honestly, there is no safe, cheap equivalent to Ozempic. Older agents such as metformin — and supplements like berberine that are sometimes marketed this way — are far weaker and are not substitutes for a GLP-1 receptor agonist. Compounded semaglutide is not an FDA-approved product, and that market has contracted sharply under FDA enforcement since semaglutide came off the shortage list. Rather than chasing gray-market 'research' retatrutide or unproven alternatives, the safer path is to discuss FDA-approved options and manufacturer savings or patient-assistance programs with a clinician.

References

  1. 1.Rosenstock J, Frías J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023. PMID: 37385280.
  2. 2.Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025. PMID: 40609566.
  3. 3.Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017. PMID: 28110911.
  4. 4.Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017. PMID: 28385659.
  5. 5.Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018. PMID: 29397376.
  6. 6.Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019. PMID: 31540867.
  7. 7.Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016. PMID: 27633186.
  8. 8.U.S. Food and Drug Administration. Ozempic (semaglutide) Drugs@FDA approval (ApplNo 209637, Dec 5 2017). Drugs@FDA. 2017. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637
  9. 9.U.S. National Library of Medicine. Ozempic (semaglutide) current FDA prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  10. 10.U.S. National Library of Medicine. TRIUMPH-2 (NCT05929079): A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT05929079
  11. 11.Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. PMID: 42810372.
  12. 12.Eli Lilly and Company. Lilly reports second-quarter 2026 financial results (Form 8-K exhibit). U.S. Securities and Exchange Commission. 2026. https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm
  13. 13.Eli Lilly and Company. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) (NCT06383390). ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT06383390
  14. 14.Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. PMID: 42250575.
  15. 15.Eli Lilly and Company. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial. PR Newswire. 2026. https://www.prnewswire.com/news-releases/lillys-retatrutide-delivered-greater-a1c-reduction-and-more-than-double-the-weight-loss-of-ozempics-highest-approved-dose-in-head-to-head-trial-302921328.html

Retatrutide vs Foundayo (orforglipron) — TRIUMPH-1 vs ATTAIN-1 cross-trial evidence

Retatrutide −25.0% TBWL at 12 mg / 80 wk (TRIUMPH-1, NEJM 2026) vs Foundayo (orforglipron) ~−11% at 17.2 mg / 72 wk (ATTAIN-1), roughly 2.2× on a cross-trial basis. Both are Eli Lilly molecules; Foundayo is FDA-approved (April 2026), retatrutide is investigational.

12 min read

Retatrutide for type 2 diabetes: TRIUMPH-2 Phase 3 results and Phase 2 evidence

Retatrutide is investigational and not FDA-approved. In TRIUMPH-2 (Lancet 2026, n=1,152, placebo-controlled), adults with obesity and T2D lost 18.8% of body weight on 12 mg vs 5.1% on placebo at 80 weeks. Lilly plans an FDA filing in Q1 2027.

18 min read

Retatrutide vs tirzepatide — TRIUMPH-1 vs SURMOUNT-1 head-to-head evidence

Retatrutide -25.0% TBWL at 12 mg / 80 wk (TRIUMPH-1, NEJM 2026) vs tirzepatide -20.9% at 15 mg / 72 wk (SURMOUNT-1), about 4 points on a cross-trial basis. Nausea, a dysesthesia signal, and discontinuation run higher, and retatrutide is not FDA-approved.

11 min read

Retatrutide TRIUMPH Phase 3: Latest Pipeline Update

In the TRIUMPH-1 phase 3 trial, Lilly's retatrutide produced up to 25.0% weight loss at 80 weeks, and 18.8% in people with type 2 diabetes in TRIUMPH-2. Lilly plans to file with the FDA in Q1 2027. Open safety questions and the access timeline are covered.

11 min read

Trulicity vs Ozempic vs Mounjaro for T2D: Head-to-Head Evidence

Trulicity (dulaglutide), Ozempic (semaglutide), and Mounjaro (tirzepatide) are the three injectable GLP-1 / GIP-GLP-1 options for T2D. We walk through SUSTAIN-7, SURPASS-2, AWARD-11, and the practical prescribing differences.

11 min read

Retatrutide vs Wegovy: cross-trial weight-loss + safety evidence (2026)

Retatrutide (investigational) -25.0% TBWL at 12 mg / 80 wk in TRIUMPH-1 vs Wegovy (FDA-approved 2021) -14.9% at 68 wk in STEP-1, about 1.7x on a cross-trial basis. No head-to-head RCT. Wegovy has SELECT (20% MACE reduction); retatrutide's outcomes trial is ongoing.

12 min read

Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

From $79/mo

sale price

Get started →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

From $129/mo

starting dose

Get started →
8.3

Found

Medication-included compounded GLP-1 on 28-day cash plans, plus insurance help for brand-name GLP-1s

Read full review →

From $169/mo

12-month plan rate

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →